Low-dose oral contraceptives in adolescents: How low can you go?

Journal of Pediatric and Adolescent Gynecology

Volumn 23, Issue 4, 2010, Pages 195-201

  Agostino, H ^a   Di Meglio, G ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Adolescent; Bone mineral density; Oral contraception

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; DEOXYPYRIDINOLINE; DESOGESTREL; ETHINYLESTRADIOL; HYDROXYPROLINE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; BONE DENSITY; BONE MINERALIZATION; CALCIUM INTAKE; CHILD; CORRELATION ANALYSIS; COUNSELING; FEMALE; FOLLOW UP; HUMAN; LITERATURE; LOW DRUG DOSE; LUMBAR SPINE; ORAL CONTRACEPTION; PRIORITY JOURNAL; PUBLICATION; SCHOOL CHILD; SHORT SURVEY; SUPPLEMENTATION; TREATMENT DURATION; URINE LEVEL; BONE DEVELOPMENT; DOSE RESPONSE; DRUG EFFECTS;

ADOLESCENT; BONE DENSITY; BONE DEVELOPMENT; CONTRACEPTIVES, ORAL, COMBINED; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHINYL ESTRADIOL; FEMALE; HUMANS;

EID: 77954028774     PISSN: 10833188     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpag.2009.11.001     Document Type: Short Survey

References (30)

1. Lu P.W., Briody J.N., Ogle G.D., et al. Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994, 9:1451-1458.
2. Sabatier J.P., Guaydier-Souquieres G., Benmalek A., et al. Evolution of lumbar bone mineral content during adolescence and adulthood: a longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women. Osteoporos Int 1999, 9:476-482.
3. Riggs B.L., Melton L.J. The prevention and treatment of osteoporosis. N Engl J Med 1992, 327:620-627.
4. Matkovic V., Jelic T., Wardlaw G.M., Ilich J.Z., Goel P.K., Wright J.K., Andon M.B., Smith K.T., Heaney R.P. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest 1994, 93:799-808.
5. Compston J.E. Sex steroids and bone. Physiol Rev 2001, 81:419-447.
6. Ludicke F., Sullivan H., Spona J., et al. Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene. Contraception 2001, 64:243-248.
7. Guide to Clinical Preventive Services 1996, US Preventive Services Task Force, Williams and Wilkins, Baltimore, MD. 2nd ed.
8. Cromer B.A., Blair J.M., Mahan J.D., et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996, 129:671-676.
9. Berenson A.B., Radecki C.M., Grady J.J., et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001, 98:576-582.
10. Cromer B.A., Stager M., Bonny A., et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 2004, 35:434-441.
11. Cromer B.A., Bonny A.E., Stager M., et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil Steril 2008, 90:2060-2067.
12. Rome E., Ziegler J., Secic M., et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J Pediatr Adolesc Gynecol 2004, 17:373-377.
13. Polatti F., Perotti F., Filippa N., et al. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 1995, 51:221-224.
14. Inman W.H., Vessey M.P., Westerholm B., et al. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970, 2:203-209.
15. Meade T.W., Haines A.P., North W.R., et al. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet 1977, 2:948-951.
16. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998, 57:315-324. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives.
17. Norris L.A., Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol 1996, 103:261-267.
18. Basdevant A., Conard J., Pelissier C., et al. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel. Contraception 1993, 48:193-204.
19. Petersen K.R., Sidelmann J., Skouby S.O., et al. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol 1993, 168:32-38.
20. Winkler U.H., Schindler A.E., Endrikat J., et al. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol. Contraception 1996, 53:75-84.
21. Middeldorp S. Oral contraceptives and the risk of venous thromboembolism. Gend Med 2005, (2 Suppl A):S3-S9.
22. results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996, 348:498-505. Ischaemic stroke and combined oral contraceptives.
23. Associated risk factors. JAMA 1975, 231:718-722. Oral contraceptives and stroke in young women.
24. Schwartz S.M., Petitti D.B., Siscovick D.S., et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 1998, 29:2277-2284.
25. Hartard M., Kleinmond C., Wiseman M., et al. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone 2007, 40:444-450.
26. Gordon C.M., Bachrach L.K., Carpenter T.O., et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008, 11:43-58.
27. Marowska J., Kobylinska M., Lukaszkiewicz J., et al. Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: normal values and clinical application. Bone 1996, 19:669-677.
28. Mora S., Pitukcheewanont P., Kaufman F.R., et al. Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999, 14:1664-1671.
29. Berenson A.B., Radecki C.M., Grady J.J., et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001, 98:576-582.
30. Paoletti A.M., Orrù M., Lello S., et al. Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. Contraception 2004, 70:293-298.